MRKMerck Sharp & Dohme LLCFinished
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Squamous Cell Carcinoma of Head and Neck
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 408 (final count)
- Started
- Aug 6, 2020
- Main results expected
- May 31, 2024
- Fully finished
- Oct 30, 2025
- Results posted
- May 25, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 45 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04428151 · record last updated 2025-12-04 · checked 2026-11-09 15:47 UTC